A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330, Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 23 Apr 2018
Price : $35 *
At a glance
- Drugs Selinexor (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 15 Apr 2018 Status changed from suspended to active, no longer recruiting.
- 21 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.